Image Source: AsiaOne
Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate GlobeNewswire August 14, 2020 UK government to purchase 60 million doses of NVX-CoV2373Novavax to partner with FUJIFILM Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UKNovavax and UK government to collaborate on Phase 3 clinical trial in UK commencing in the third quarter of this yearNovavax intends to make additional capacity available to global markets GAITHERSBURG, Md., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has signed a Heads of Terms (Term Sheet) with the Government of the United Kingdom (UK) for the purchase of 60 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine, and a Phase 3 clinical trial to assess the efficacy of the vaccine in the UK population.
Source: AsiaOne